Predicting the Progression of Very Early Systemic Sclerosis: Current Insights.

Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease with distinct pathological hallmarks (ie, inflammation, vasculopathy, fibrosis) that may predominate at different stages in the disease course with varying severity. Initial efforts to classify patients with SSc identified a subset of patients with very early SSc. These patients possessed signs of SSc (eg, Raynaud phenomenon, SSc specific autoantibodies and/or nailfold capillary abnormalities) without fulfilling complete SSc classification criteria. Recognizing the inherent value in early diagnosis and intervention in SSc, researchers have endeavored to identify risk factors for progression from very early SSc to definite SSc. The present review summarizes the clinical phenotype of patients with very early and early SSc. Through a scoping review of recent literature, this review also describes risk factors for progression to definite SSc with a focus on the specific clinical features that arise early in the SSc disease course (eg, diffuse cutaneous sclerosis, interstitial lung disease, esophageal dysfunction, renal crisis, cardiac involvement). In addition to clinical risk factors, this review provides evidence for how biological data (ie, serological, genomic, proteomic profiles, skin bioengineering methods) can be integrated into risk assessment models in the future. Furthering our understanding of biological features of very early SSc will undoubtedly provide novel insights into SSc pathogenesis and may illuminate new therapeutic targets to prevent progression of SSc.

Introduction

Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease with significant heterogeneity in disease course and clinical outcomes. Affecting multiple organ systems and to varying degrees, SSc has the highest cause-specific mortality among all connective tissue diseases.1 Marked diversity exists in the evolution of SSc-related disease progression, disease manifestations and treatment response rates between patients.2 For this reason, when a patient receives a diagnosis of SSc, multiple questions immediately emerge, ranging from “How long do I have to live?” to “Will I develop lung disease?” This prognostic uncertainty poses challenges to patients and their providers.

Data from clinical trials and observational cohorts, along with direct clinical observations, have furthered our understanding of the unique clinical phenotypes associated with SSc. Increasingly, specific patient data are gathered to predict disease course and organ involvement early in SSc. These data include demographic characteristics, presenting disease features, laboratory analyses, radiographic studies and functional tests. The seasoned SSc practitioner uses these data to educate the patient on their anticipated prognosis and develop an initial monitoring and treatment plan. However, risk stratification in SSc remains an evolving area of research,3 and valid SSc-prediction tools do not exist.

In addition, patients with very early SSc may exhibit few manifestations of SSc at the time of their presentation (eg, Raynaud phenomenon [RP], positive anti-nuclear antibody [ANA], abnormal nailfold capillaroscopy).4 With these scarce data, the practitioner must then generate a gestalt regarding the likelihood this patient will develop SSc and the time course for disease progression. This review article describes how to predict disease progression in a patient with very early SSc with a focus on practical and readily available clinical and biological assessments. This review also explores novel ways to predict disease progression with a focus on genetic biomarkers and the gastrointestinal (GI) microbiome. The overall goal of this review is to provide a practical guide for monitoring patients with very early SSc through careful history taking, physical examination and evidence-based studies.

Very Early Ssc

In the literature, the terms very early SSc and early SSc have been often used interchangeably to indicate the preclinical phases of SSc with signs of RP, but not skin or internal organ involvement (these terms include very early SSc, early SSc [abbreviated as EaSSc], preclinical systemic sclerosis [PreSSc], undifferentiated connective tissue disease at risk for systemic sclerosis [UCTD-risk-SSc]). However, very early and early SSc have distinct clinical meanings. To avoid confusion, in the present review, we refer to very early SSc as the stages prior to a definite diagnosis of SSc and to early SSc as the first phases of SSc with an already definite, but recent SSc diagnosis (<3 years). Both of these representative disease stages are important to identify, as early recognition of these stages may improve outcomes for patients.

Definitions of Very Early SSc

In 2001, LeRoy and Medsger proposed criteria to individuate and classify patients at a very early stage and who did not completely satisfy The American Rheumatism Association (ARA) preliminary criteria for SSc proposed in the 1980.5 They labeled patients with RP, SSc specific autoantibodies and/or typical abnormalities at nailfold capillaroscopy (Figure 1) as limited SSc (not to be confused with limited cutaneous SSc).5 In 2008, a study from a Canadian group investigated 586 consecutive patients presenting with RP and reported that among patients with capillaroscopy abnormalities and specific autoantibodies, 65.9% and 72.7% of patients progressed to definite SSc in 5 and 10 years, respectively, according to ARA preliminary criteria.6 This study represented a preliminary validation of the LeRoy and Medsger criteria for very early SSc and identified specific risk factors for progression to definite SSc.

Figure 1

(A and B) demonstrate nailfold video-capillaroscopy findings in a patient with very early SSc who presented with RP and anticentromere antibodies. Arrows in (A) identify giant capillaries. (B) demonstrates capillary drop-out; the arrow in this panel identifies a microhemorrhage.

In 2011, the European League Against Rheumatism (EULAR) Scleroderma Trial and Research (EUSTAR) proposed criteria for a very early diagnosis of SSc (VEDOSS) based on a Delphi consensus study. In this study, physicians from 85 EUSTAR centers identified RP, the presence of puffy fingers and antinuclear antibodies (ANA) positivity as key features and the presence of SSc specific autoantibodies (anti-centromere antibody or anti-topoisomerase I) and SSc pattern on nailfold capillaroscopy as necessary features for a very early diagnosis of SSc.7

In 2013, a EUSTAR study of 469 patients with RP demonstrated that high suspicion of very early SSc was represented by the presence of ANA positivity and puffy fingers.8 In the same year, the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for SSc were published, and reported a higher specificity and sensitivity for SSc than the ARA criteria.9 The 2013 ACR/EULAR criteria include clinical features of the LeRoy and Medsger criteria for very early SSc (eg, RP, SSc specific antibodies and/or SSc pattern at capillaroscopy), as well as the VEDOSS criteria (RP, ANA positivity, SSc specific antibodies, SSc pattern at capillaroscopy, puffy swollen digits) (Table 1). While a score of 9 is the minimum score required to classify a patient with definite SSc, patients fulfilling the Le Roy and Medsger criteria for very early SSc and the VEDOSS criteria will have a maximum score of 8 (Figure 2). Identifying preclinical SSc represents an important diagnostic opportunity as preventative treatment strategies (an unmet area of research) could be administered during this time window.10

Table 1

Criteria for Very Early SSc Based on the LeRoy and Medsger Definition5 and the VEDOSS Criteria7

Features	LeRoy and Medsger Definition of Very Early SSc	VEDOSS Criteria for Very Early SSc
Raynaud Phenomenon	X	X
SSc-specific autoantibodies	X	X
SSc features on capillaroscopy	X	X
Puffy fingers		X
Positive ANA		X

Figure 2

The ACR/EULAR 2013 Classification Criteria for SSc, highlighting the criteria for very early SSc. A total score of 9 is sufficient to classify patients with definite SSc.

Recently, in 2021, VEDOSS criteria were prospectively validated in a EUSTAR multicenter study that investigated the clinical values of VEDOSS criteria in detecting SSc clinical progression. This study followed 1150 subjects with RP, of whom 553 met VEDOSS criteria and had available data at follow-up.11 Disease progression was defined as the fulfillment of ACR/EULAR classification criteria for SSc. Of the 553 patients, 254 experienced progression or reached 5-year follow-up. The overall rate of progression in 5 years was of 52.4%, aligning with the previous data from Koenig et al.6 The study also reported that the absence of the ANA decreased the risk of progression to SSc, while ANA positivity together with the presence of puffy fingers predicted the highest rate of progression to definite SSc. Interestingly, patients with a positive ANA, SSc specific autoantibodies and puffy fingers had the highest progression rate over time (94.1%), followed by patients with ANA, specific autoantibodies and capillaroscopic abnormalities (82.2%).

Another recent study on 217 subjects with RP and at least one manifestation of SSc also demonstrated that the combination of ANA positivity and puffy fingers were the two features most strongly associated with disease progression.12

Clinical Features of Very Early SSc

As described above, based on 2001 LeRoy and Medsger criteria or on VEDOSS criteria, subjects at a very early SSc stage can present with RP plus ANA and/or SSc specific antibodies and/or scleroderma pattern at nailfold capillaroscopy and/or puffy fingers without any other skin or organ involvement.5,7 Nevertheless, some studies have demonstrated subclinical organ involvement in very early SSc stages. For example, one study reported that 42% of 19 patients with very early SSc had signs of early SSc-cardiac involvement (ie, defined as an inverted mitral E/A ratio), diffusion impairment (ie, a diffusing lung capacity for carbon monoxide [DLCO] <80% of the predictive value) and/or esophageal involvement (ie, based on a low esophageal sphincter pressure <15 mmHg).13 In another cohort followed by the same investigators, 48.7% of 39 very early SSc patients presented at baseline at least one of the clinical involvements described above and/or decreased lung function (ie, forced vital capacity [FVC]< 80% predicted).14 Another study found evidence of GI tract involvement in 59 patients meeting VEDOSS criteria compared to 24 healthy controls, reporting alterations of esophageal as well as anorectal manometry in very early SSc patients.15 However, one study investigating cardiac autonomic modulation in SSc patients, healthy controls and very early SSc patients demonstrated that heart rate variability was not impaired in very early SSc subjects who had comparable indexes to the healthy controls.16

Importance of Identifying Very Early SSc

Recognition of the preclinical phase of SSc could potentially help identify early signs of internal organ involvement.17 From a clinical perspective, the early diagnosis may guide screening and risk stratification efforts and facilitate therapeutic interventions at an earlier time point in the disease course. From the research side, understanding the biomolecular and clinical features of the preclinical phases may reveal important insights into the pathogenesis of SSc, as well as therapeutic targets. Research on this preclinical disease stage may help us to understand why some patients progress rapidly into a definite diagnosis, while others exhibit stable very early SSc features for several years before progression to definite SSc. While patients with very early SSc may not present at the same frequency to a rheumatologist as those with obvious SSc, efforts are needed to ensure these patients are seen by rheumatologists and preferably those with an expertise in SSc.

Risk Stratification

As described above, risk stratification is a cornerstone to the initial evaluation of a patient with early SSc. The presence or absence of specific clinical and biological factors can provide insight into the future course of disease.18 A simple way to approach risk stratification is to consider risk by organ system (Table 2; Figure 3). Specifically, the practitioner evaluates the risk of development/progression of specific manifestations, separately by organ system. This organized approach not only allows the practitioner to apply evidence-based medicine to their evaluation process, but it also may improve their ability to effectively communicate their evaluation and findings to the patient. Because this review focuses on progression in very early and early SSc, risk stratification strategies will be described for SSc manifestations that arise earlier in the SSc disease course (cutaneous fibrosis, interstitial lung disease [ILD], renal crisis, cardiac involvement, digital ulcers, and upper GI tract involvement).13,19 While the timing from RP to the first non-RP manifestation of SSc varies, a recent longitudinal study of the EUSTAR cohort (median follow up time of 2.1 years) demonstrated that the median time was 0.9 (IQR 0–4.2) years.19

Table 2

Initial Evaluation of a Patient with Very Early or Early SSc

Category	Focused Evaluation Strategies
Patient history	Temporal evaluation of specific SSc symptoms (eg, Raynaud phenomenon, first non-Raynaud symptom, puffy fingers, tendon friction rubs, digital ulcers)
Physical examination	Thorough examination of all organ systems with special focus on skin and nailfold capillaries
Laboratory evaluation	Hemoglobin
	Creatinine
	Creatine kinase
	C-reactive protein
	Comprehensive SSc autoantibody panel
Diagnostic studies	Chest X-ray
	HRCT chest – highly recommended in all cases
	Transthoracic echocardiogram
	Pulmonary function tests
	Video-capillaroscopy
Invasive studies	Upper endoscopy in select cases

Figure 3

Flow chart for the evaluation of patients with early SSc by organ system with description of risk factors and diagnostic testing.

Skin Fibrosis

The skin is the most common organ system involved in SSc, affecting 95% of patients.19 While a minority of patients may present with scleroderma sine scleroderma,20 most will exhibit skin fibrosis over the course of their disease. The two major subgroups of skin disease in SSc (ie, limited [lcSSc] and diffuse [dcSSc] cutaneous SSc) are determined based on physical examination.21 Patients with lcSSc may have involvement of the hands, forearms, feet, lower legs and face, while patients with dcSSc may have involvement of these areas, as well as the trunk, chest, upper arms and thighs. When evaluating a patient with very early or early SSc, certain historical clues may help the practitioner determine the risk of developing diffuse cutaneous SSc.22 For example, when a given patient develops their first non-Raynaud symptom of SSc (eg, puffy hands) within 1–2 years of the onset of Raynaud phenomenon, this can suggest a greater likelihood that this patient will develop diffuse cutaneous sclerosis.23 In contrast, when a given patient develops their first non-Raynaud symptom of SSc more than 5 years after the onset of Raynaud phenomenon, this can suggest a greater likelihood that this patient will develop limited cutaneous sclerosis.23 Therefore, we recommend that practitioners record the estimated start date for each symptom attributable to SSc and generate a timeline in the patient’s chart. This simple task can provide invaluable insight into the temporal evaluation of SSc.

In addition to obtaining a thorough patient history, documentation and interpretation of demographic characteristics is prudent during risk stratification. Male sex23 and African American race24 are each associated with a greater likelihood of developing diffuse cutaneous sclerosis. This does not mean that male patients will always have diffuse cutaneous disease; however, their probability for having this clinical phenotype is greater.

During the physical examination, the presence of certain signs may be a harbinger for the development of diffuse cutaneous disease. For example, identification of cutaneous patches of hypo/hyperpigmentation may signify that the patient will develop diffuse cutaneous sclerosis.25 Signs of excoriation from scratching could suggest urticaria, a defining feature of early cutaneous inflammation in diffuse cutaneous SSc. Moreover, the development of forearm inflammation/fibrosis shortly after the onset of puffy hands (ie, within weeks to months) could indicate that diffuse progression of cutaneous sclerosis is imminent.26 Tendon friction rubs are also a feature of early diffuse cutaneous sclerosis.27 In addition, more extensive nailfold capillary changes are often observed in patients with early diffuse versus limited cutaneous SSc.27

Laboratory analysis is an essential component of the initial assessment in a patient with very early or early SSc. Assessment of basic laboratory studies, as well as autoimmune serologies, yields important prognostic data. For example, elevated C-reactive protein (CRP) and/or elevated interleukin (IL)-6 not explained by an alternative cause, such as infection, could also indicate a greater likelihood of diffuse cutaneous sclerosis.28 Similarly, a modestly elevated creatine kinase (CK) is a sign of SSc-related fibrosing myopathy, a condition more commonly seen in patients with dcSSc than lcSSc.29 Certain autoantibodies are associated with cutaneous subtype (Table 3). For example, anti-centromere antibodies are associated with limited cutaneous disease, while anti-Scl-70 antibodies are associated with diffuse cutaneous disease.3 Anti-RNA polymerase III antibodies are also associated with diffuse cutaneous disease; very early and early SSc patients who possess the latter antibodies are at risk for rapidly progressively skin disease.30 Evaluation for these autoantibodies should occur at the time of initial presentation. Moreover, autoantibodies may be present several years before the clinical detection of SSc.31 Care is needed when selecting the autoantibody detection method, as certain methods (eg, multiple-bead, enzyme-linked immunosorbent assay) can lead to a higher likelihood of a false positive result for the anti-Scl-70 antibody test.32

Table 3

Clinical Correlates of Autoantibody Profiles in SSc

Autoantibody	Cutaneous Subtype	SSc Features
Anti-Scl-70	Diffuse	Progressive ILD
Anti-RNA polymerase III	Diffuse	Renal crisis, GAVE
Anti-centromere	Limited	PAH
Anti-Th/To	Limited	ILD, PAH
U3-RNP	Limited and diffuse	PAH, inflammatory myositis
U11/U12 RNP	Limited and diffuse	ILD
Ku	Limited and diffuse	ILD, inflammatory myositis
Pm/Scl	Limited	Inflammatory arthritis, ILD, calcinosis, overlap syndromes (eg, myositis)
U1RNP	Limited	ILD, overlap syndromes (eg, mixed connective tissue disease)

Note: References for Table:3,122–128.

Skin biopsies are not commonly used in clinical practice to diagnose SSc; however, emerging research from gene expression studies in the skin of patients with SSc has demonstrated distinct gene expression signatures present at an early stage of disease. For example, in patients with early dcSSc, innate and adaptive immune cell signatures are increased compared with SSc patients with longer disease duration.33

Interstitial Lung Disease

ILD is the leading cause of SSc-related death34 and the complication that many patients fear the most. While the most reliable and sensitive way to detect early ILD is to obtain high-resolution computed tomography of the chest,35 patients with very early SSc may not have access to this type of imaging. Furthermore, the risk of radiation exposure may outweigh the perceivable benefit of obtaining a high-resolution computed tomography (HRCT) for some practitioners. In these scenarios, risk stratification may help guide the decision to obtain an HRCT of the chest.

On history, patients with very early or early SSc may complain of fatigue. While fatigue has multiple etiologies in SSc,36 fatigue that occurs with or after exertion could be an early sign of reduced gas exchange due to parenchymal lung disease. Typically, dyspnea on exertion or at rest due to ILD does not develop at this early disease stage, and alternate causes (eg, deconditioning, coronary artery disease) should be considered if a patient with very early or early SSc presents with dyspnea.

Similar to diffuse cutaneous sclerosis, male sex37 and African American race24 are independently associated with a greater risk of developing ILD. Patients with certain overlap connective tissue diseases also associated with ILD (eg, myositis) may be at higher risk for developing ILD. On physical examination, the presence of bibasilar crackles can signify early interstitial lung abnormality. Clubbing is exceedingly rare in SSc and would not be expected to occur at an early disease stage of SSc. Similarly, resting hypoxemia and desaturation on a six-minute walk (6MWT) are also not expected in very early or early SSc. However, measuring oxygen saturation at rest and during 6MWT in these patients is important for establishing a baseline for future assessments of disease progression. Emerging evidence suggest that specific nailfold capillary patterns may predict the presence of ILD;38 however, larger prospective studies are needed to affirm this hypothesis.

Specific laboratory tests may raise suspicion for the presence of ILD, including an elevated CRP concentration in the circulation.39 Candidate biomarkers currently under investigation, such as Krebs von den Lungen 6 (KL-6) and surfactant protein-D (SP-D), are associated with ILD progression. KL-6 is a pneumoprotein that at baseline predicts the decline of FVC over time and correlates with ILD severity. Moreover, therapeutic intervention for ILD is associated with a decline in KL-6.40–43 SP-D levels correlate with severity of ILD and predict response to rituximab for the treatment of ILD.44–46 Similar to CRP, increased serum levels of interleukin (IL)-6 are associated with progression of ILD and mortality.47 Treatment targeting the IL-6 receptor was found to stabilize lung function compared with placebo in a relatively small study of patients with dcSSc with risk factors for ILD progression at baseline (eg, progressive skin disease, elevated inflammatory markers).48

Serological profiling can also help risk stratify patients. For example, the presence of anti-Scl-70 antibodies, also referred to as anti-topoisomerase antibodies, portend a greater risk of developing progressive ILD, while the presence of anti-centromere and anti-RNA polymerase III antibodies, portend a lower risk of developing progressive ILD (Table 3).3

Rarely, a patient with very early or early SSc will have historical pulmonary function test (PFT) results available for comparison. If available, a reduction in the DLCO can signify early ILD. Typically, the DLCO declines prior to the FVC in early ILD.35 Similar to the 6MWT, PFTs are important to obtain in all patients with very early or early SSc to establish baseline values for monitoring future disease progression. Although PFTs represent a cornerstone for non-invasive monitoring of ILD, HRCT more sensitively detects early ILD and should be performed in all patients with a definite diagnosis of SSc regardless of PFT results.35,49 In early SSc-ILD, radiographic features include ground glass opacity with possible subtle reticulations, in the bilateral lower lobes. The predominant radiographic pattern of SSc-ILD is non-specific interstitial pneumonia (NSIP), characterized by bilateral reticulation, ground glass opacities and traction bronchiectasis. Usual interstitial pneumonia (UIP) occurs in approximately 25% of patients with SSc-ILD.50

In some instances, patients will have undergone an X-ray of the chest for other reasons. Chest X-ray is neither sensitive, nor specific for ILD in SSc;51 however, any signs of bibasilar abnormalities should prompt the practitioner to order an HRCT of the chest. In early SSc-ILD, distinguishing between interstitial abnormality due to SSc and atelectasis can be challenging. Obtaining prone imaging is helpful in these scenarios.52 It is also important to note that ILD may occur as the presenting feature of SSc in some cases. For instance, a recent study of a large US health insurance database demonstrated that 4–6% of patients had claims for ILD more than one year prior to a claim for SSc.53 These patients may have features of SSc at the time of the ILD diagnosis that are more subtle and go unrecognized by their primary physician and/or pulmonologist.

Renal Disease

Renal crisis typically occurs early in the course of SSc, particularly in patients with dcSSc.18 Early signs of renal crisis include a rise in systolic blood pressure, as well as nausea with or without vomiting. Also, non-specific symptoms such as headache, vision abnormalities and weight gain can occur along with new onset anemia and thrombocytopenia. These signs and symptoms are due to new onset of hypertension, progressive renal failure, congestive heart failure, hypertensive encephalopathy and microangiopathic hemolytic anemia.54 Many patients are asymptomatic in the early phases of renal crisis and careful identification of risk factors for renal crisis is vital at this disease stage. Known risk factors for renal crisis include diffuse cutaneous skin disease, early disease, African American race, pericardial effusion, recent use of prednisone >15 mg/day and the presence of anti-RNA polymerase III antibodies.55 In a retrospective study performed on military medical records, the presence of three or more of the following features at the time of SSc diagnosis predicted future renal crisis: proteinuria, anemia, hypertension, chronic kidney disease, elevated erythrocyte sedimentation rate, thrombocytopenia, hypothyroidism and serum anti-Ro antibody positivity.56 Other risk factors that are associated with SRC are the presence of tendon friction rubs, joints contractures and pericardial effusion.57 Acute kidney injury is typically not present in the early stages of renal crisis; however, measuring the creatinine and estimating the glomerular filtration rate in the initial evaluation of a patient with early or very early SSc is important for establishing a baseline level of kidney function. Also, measuring blood pressure is an easy tool for the early detection of renal crisis in SSc and can be performed at home by the patient between clinic visits. The differential diagnosis for scleroderma renal crisis includes pre-renal causes such as volume depletion, toxicity from medications, such as calcineurin inhibitors, membranous nephropathy, pre-eclampsia and ANCA-associated vasculitis.57

Cardiac Complications

Cardiac involvement is an uncommon presenting feature of very early or early SSc. Diverse manifestations of cardiac involvement exist, ranging from arrhythmias to impaired ventricular relaxation.58 Patients with SSc may exhibit signs of pericardial disease (eg, acute or chronic pericarditis, pericardial fibrosis, pericardial effusion, tamponade), myocardial disease (eg, fibrosis, ventricular diastolic or systolic dysfunction, myocarditis), conduction system disease (eg, heart block, supraventricular arrhythmias, ventricular arrhythmias, autonomic dysfunction) and vascular disease (eg, mural fibrosis, intimal proliferation, platelet-fibrin clotting).59

Predicting the likelihood of developing cardiac disease in a patient with early or very early SSc is challenging. Due to the heterogeneity of cardiac manifestations and the lack of clinical trials in this area, our understanding of risk factors for specific cardiac features is limited. The skin-thickness-progression rate may help identify patients at risk for cardiac disease. A single-center study demonstrated that patients with rapid cutaneous progression were more likely to have severe cardiac disease compared with patients with slow cutaneous progression; however, the difference was relatively small (3% versus 1%, respectively).22 While the presence of diffuse cutaneous disease is a risk factor for cardiac involvement in SSc, patients with limited cutaneous sclerosis are not immune to this feature of SSc.60 Cardiac involvement may occur in both cutaneous subtypes.61

On physical examination, signs of early SSc-cardiac involvement may include presence of rales, murmurs and arrhythmias. Jugular venous distension, hepatomegaly and lower extremity are less likely to occur early in the SSc disease course. Various diagnostic modalities for SSc-cardiac involvement exist. In a patient with early or very early SSc, obtaining an ECG, chest X-ray and echocardiogram may help screen for early cardiac dysfunction. If there is strong clinical suspicion for an arrhythmia (eg, palpitations, syncope), a 24-hour ambulatory ECG detects a higher prevalence of conduction abnormalities compared with resting ECG in patients with SSc.62

Also, recent evidences show that cardiac involvement can occur in asymptomatic patients with SSc.63 Certain biomarkers and studies can suggest the presence of cardiac involvement; these include troponin I, N-terminal pro-hormone BNP (NT-proBNP), echocardiography and ECG.63 For example, the presence of fragmented QRS complexes on ECG (defined as an additional R wave, or notching of the R or S wave, or the presence of fragmentation in two contiguous leads) could suggest cardiac fibrosis.64–66 In addition, cardiac MRI with T2-weighted images and early gadolinium enhancement and late gadolinium enhancement are used to evaluate for myocardial involvement. A recent study demonstrated that the measurement of T1 signal (the T1 mapping) can detect early cardiac fibrosis.67 One of the most common findings in asymptomatic cardiac involvement is the presence of a diastolic cardiac dysfunction but, of note, some early alterations detected in asymptomatic SSc patients can be reversible while symptomatic patients are more prone to show a progression of the cardiac impairment.68,69 While this is an evolving area of clinical research, an accurate evaluation of the cardiac function should also be performed in early SSc.

Pulmonary Hypertension

Pulmonary hypertension (PH) often develops later in the course of SSc.70 However, sometimes patients with pulmonary arterial hypertension (PAH) are misdiagnosed with idiopathic PAH if they have more subtle signs of SSc (mild Raynaud phenomenon, telangiectasias) at their time of initial presentation. These patients usual experience a delayed referral to rheumatology contingent on their development of more overt clinical signs of SSc and/or their insufficient response to PAH therapies. Patients with SSc-PAH often have worse outcomes than patients with idiopathic PAH.71

Observational studies have demonstrated that male sex, SSc disease duration >10 years and a DLCO <55% are risk factors for SSc-PAH.72 Studies have also reported early onset (within 5 years of SSc diagnosis since first non-Raynaud symptoms) of PAH in dcSSc patients. Moreover, early onset of SSc-PAH is associated with more severe vascular disease than late onset SSc-PAH.73,74

Valid algorithms exist to help select patients for evaluation for PAH using a right heart catheterization.75 These algorithms include the measurement of proBNP, presence of telangiectasias on physical examination, measurement of serum urate, presence of right axis deviation on ECG and the detection of anticentromere antibodies. While it may be premature to obtain a proBNP on all patients with early or very early SSc, the other algorithm components are feasible to obtain and may help identify early pulmonary vascular disease. However, even in the absence of the aforementioned risk factors, routine annual screening for PAH via echocardiogram is recommended by the American Heart Association and American College of Cardiology Foundation.76 Patients who have suspected PAH from echocardiogram should be referred for right heart catheterization to obtain direct measurements of pulmonary arterial pressures. Patients whose diagnosis of PAH resulted from routine screening had improved survival compared with patients who were not screened.77 Regular screening is thus of fundamental importance to detect PAH in its earliest phases. Discovering additional biomarkers to identify patients at risk for PAH is an ongoing area of research. A recent study measured 313 proteins from the serum of patients with SSc both with and without PAH in the DETECT study cohort. After performing validation in an external cohort, eight proteins (among them NT-ProBNP) were able to distinguish PAH from non-PAH.78

Upper Gastrointestinal Tract Involvement

The upper GI tract is typically affected early in the course of SSc.79 After Raynaud phenomenon, symptoms of upper GI tract involvement (eg, reflux, heartburn, dysphagia) often occur as the first or second non-Raynaud symptom in SSc.80 Any patient with a history of new onset reflux disease (in the absence of a change in dietary patterns, lifestyle or body habitus or pregnancy), who also reports a relatively recent history of Raynaud phenomenon should be evaluated for SSc. Predicting progression of upper GI involvement in very early or early SSc is difficult as some patients lack symptoms, even when there is objective evidence of esophageal disease (eg, esophagitis).

In a patient with newly diagnosed early SSc, an acute drop in hemoglobin could suggest the presence of gastric antral vascular ectasias (GAVE), a serious complication that can result in rapid blood loss.81 GAVE occurs earlier in the disease course of patients with dcSS and often later in the disease course of patients with lcSSc.82

Given the association between esophageal dysfunction and ILD,83,84 patients who exhibit signs of ILD progression may also have progressive involvement of their esophagus (ie, absent contractility). Esophageal dilation on HRCT of the chest is a common finding in SSc patients and its clinical significance is unknown. While some studies have demonstrated correlations between esophageal dilation and severity of ILD, a recent study found no relationship between two quantitative radiographic measures of esophageal dilation and ILD severity or progression.85,86 In many patients, esophageal-related symptoms may be silent or may be less apparent to the patient than their respiratory symptoms. These patients should undergo thorough evaluation for upper GI involvement. This may include manometry with pH monitoring and upper endoscopy.

Vascular Manifestations

RP is often the first sign of SSc and can occur several years before the onset of the first non-RP sign of SSc in some patients. While primary RP is relatively common in women, certain characteristics can suggest the presence of secondary RP, such as first appearance of RP in later adulthood, asymmetry of the RP, presence of RP with a minimal temperature changes, and the presence of digital ulcers or pitting scars.87 In SSc, RP is associated with structural vascular modifications with imbalance of vasoconstrictor and vasodilator factors.88 Capillaroscopy and autoantibody profiling are recommended to help identify very early stage SSc. Capillaroscopy can show a “scleroderma pattern”, characterized by giant capillaries, hemorrhages, ramified capillary loops and/or avascular areas.89 Currently the classification includes three distinct phases, early, active and late, that are associated with SSc disease duration.90

Certain patients with very early or early SSc are at risk for the development of digital ulcer disease.91 Early identification of these at-risk patients is central to therapeutic decision making for the management of RP. Studies have demonstrated that specific nailfold capillary patterns independently predict the risk of developing digital ulcers in patients without a history of digital ulcers.92 For example, the presence of avascular areas on capillaroscopy is associated with a higher risk of digital ulcers.93 In addition, multi-center observational studies have demonstrated that SSc patients with an Scl-70 antibody develop digital ulcers approximately 5 years earlier than those who were anti-centromere positive.94

Novel Methods to Identify Risk of Disease Progression

Novel methods are under investigation to help identify patients with very early or early SSc most at risk for disease progression. Below is a summary of some of the most promising methods and their clinical applicability.

Gene and Gene Expression Studies

Multiple genetic variations of human leukocyte antigen (HLA) region associated genes are associated with SSc.95,96 In addition, polymorphisms among non-HLA genes may increase the risk of developing SSc, including polymorphisms of type I interferon regulatory factors, as well as of genes expressed by T lymphocytes (STAT4, CD247, IL12) or by B lymphocytes.97,98

Biomolecular profiling via gene expression studies may help to identify patients at greater risk of disease progression based on studies performed in cohorts of patients with established SSc.99 Prediction studies on early SSc often focus on early dcSSc. For example, recent studies reported that both innate and adaptive immunity signatures are present in early dcSSc,33 and that these skin signatures can normalize over time in dcSSc.100

Biomolecular alterations are likely present in the preclinical stages of SSc. A study analyzed the whole blood of 19 patients with very early SSc, 30 healthy controls, 12 patients with primary RP and 7 patients with early SSc and evaluated the expression of a limited panel of IFN type I inducible genes. This study detected a type I IFN signature in very early and early SSc patients and found a correlation between monocyte IFN scores and monocyte BAFF mRNA levels.101

Protein Studies

Studies investigating circulating proteins in patients with very early SSc have largely examined a limited number of serum proteins involved in pro-inflammatory and pro-fibrotic pathways (Figure 4). In a study of 24 patients with very early SSc, 48 patients with early SSc and 24 control patients with osteoarthritis/fibromyalgia, higher levels of sICAM-1, CCL2, CXCL8, IL-13 and IL-33 were present in very early SSc patients compared with controls.102 Another study evaluated cytokine production from CD56+ NK/NKT cells in 24 patients with very early SSc (labeled as EaSSc), 10 patients with primary RP, 12 patients with early SSc and 9 healthy controls. This study demonstrated an increase of IL-6, TNF-α and MIP-1α/CCL3 following TLR1/2 stimulation in very early SSc and especially in early SSc compared with controls.103 Significantly elevated serum levels of CXCL10, CXCL11, TNFR2 and CHI3L1 were observed in two different cohorts of very early SSc and early SSc compared with healthy controls.104 Also, a study on 34 patients fulfilling VEDOSS criteria and 29 patients with definite SSc demonstrated higher serum levels of CXCL10 and CXCL11 in patients fulfilling the VEDOSS criteria.105 Studies have also evaluated the role of angiogenic molecules in the earliest phases of SSc. In one study of 43 patients with SSc, 9 patients with very early SSc (labeled as PreSSc) and healthy controls, VEGF serum levels were increased in very early SSc compared with controls.106 Moreover, a subsequent study found that endostatin serum levels were higher not only in established SSc but also in a subgroup of patients with very early SSc suggesting that vascular modifications are already ongoing in the preclinical stages of SSc.107 Consistent with these findings, other studies have demonstrated increased VEGF, reduced capillarogenesis, increased level of the antiangiogenic chemokine CXCL4 and activation of antiangiogenic mechanisms in patients meeting VEDOSS criteria.108–110 While the sample sizes of these studies are small, increasing the likelihood of type 1 error, the findings seem to suggest a pro-inflammatory, anti-angiogenic immune signature in patients with very early SSc.

Figure 4

Proteins related to very early SSc disease stages.

Microbiome Studies

Investigation of the GI microbiota provides insights into the complex interaction between the immune system with the bacterial flora.111 Several studies were conducted in inflammatory bowel diseases as well as in systemic autoimmune diseases (SADs) finding specific alterations of GI microbiota in patients compared with healthy controls or within different groups of SADs.112–114 In SSc, recent studies demonstrated a reduction of pro-tolerogenic bacteria species in SSc versus healthy controls, as well a different composition of gut microbiota in SSc with or without GI involvement.115–117 An important question arises about whether these microbiota alterations, toward a decrease of commensal bacteria and increase of pro-inflammatory strains, are more a cause or a consequence of the autoimmune diseases especially when a GI disease involvement is present.118 To answer to this question, studies on very early SSc are needed as well as longitudinal studies to assess the modification of gut microbiota composition over time. Interestingly, a study to evaluate gut microbiota in two geographically different cohorts (one from Sweden and the UCLA cohort from the USA), evaluated SSc patients with long disease duration as well as early SSc with recent diagnosis (median disease duration of 2.0 years).85 This study demonstrated a reduction of commensal bacteria and increase of pathobiont genera in the early SSc group when compared to healthy controls.119 Interestingly, in both of the cohorts, the presence of interstitial lung disease, small intestinal bacterial overgrowth, immunosuppression and disease duration was associated with beta diversity (ie, the microbial composition similarity between-subject, which enables the identification of differences between samples within a group).119 Future, longitudinal studies of patients with very early and early SSc are needed to explore the role of microbiome in disease progression.

Skin Bioengineering Methods

Evaluation of skin mechanical properties could be a way to detect skin progression at a very early stage of disease; ie, the analysis of viscoelasticity of skin in association with data from capillaroscopy could intercept SSc skin involvement and progression.120 Changes in viscoelasticity have been observed in skin of patients with secondary RP distinguishing them from subjects with a primary RP.121

Conclusion

In summary, very early SSc and early SSc are clinically important disease stages of SSc and represent an evolving area of research. While these patients often comprise a minority of SSc patients followed at expert SSc centers, and while the clinical burden of disease is low at this stage, these patients should nonetheless be followed closely with comprehensive clinical evaluation. In addition to a careful history and physical examination, complete autoantibody profile and capillaroscopy, PFT with DLCO assessment, HRCT chest, serological studies, as well as echocardiography are needed. When clinical risk factors for disease progression or for disease worsening are present, further diagnostic testing is needed to evaluate for cutaneous and internal organ involvement and progression.

While our ability to predict the overall risk of progression from very early SSc to definite SSc is still somewhat limited, recent advancements in research (eg, the longitudinal validation of VEDOSS criteria) have propelled this field forward paving the way for future studies examining clinical and biomolecular profiles of the preclinical phase. These future studies have the potential to provide novel insights on SSc pathogenesis and reveal new therapeutic targets aimed at curtailing or even reversing the progression of this chronic and disabling disease.